NeoGenomics, Inc. (NEO) Shares Bought by Uniplan Investment Counsel Inc.

Uniplan Investment Counsel Inc. increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 7.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 839,310 shares of the medical research company’s stock after purchasing an additional 55,506 shares during the period. Uniplan Investment Counsel Inc. owned 1.06% of NeoGenomics worth $9,341,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of NEO. Royce & Associates LP boosted its stake in shares of NeoGenomics by 57.5% during the 2nd quarter. Royce & Associates LP now owns 955,900 shares of the medical research company’s stock worth $8,565,000 after purchasing an additional 348,900 shares during the period. Blair William & Co. IL boosted its stake in shares of NeoGenomics by 8.1% during the 2nd quarter. Blair William & Co. IL now owns 377,672 shares of the medical research company’s stock worth $3,384,000 after purchasing an additional 28,213 shares during the period. Cadence Capital Management LLC lifted its holdings in NeoGenomics by 5.8% during the 2nd quarter. Cadence Capital Management LLC now owns 150,419 shares of the medical research company’s stock valued at $1,348,000 after buying an additional 8,241 shares in the last quarter. Falcon Point Capital LLC lifted its holdings in NeoGenomics by 338.6% during the 2nd quarter. Falcon Point Capital LLC now owns 1,100,474 shares of the medical research company’s stock valued at $9,860,000 after buying an additional 849,589 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in NeoGenomics by 79.2% during the 2nd quarter. Goldman Sachs Group Inc. now owns 30,678 shares of the medical research company’s stock valued at $275,000 after buying an additional 13,561 shares in the last quarter. 83.43% of the stock is owned by institutional investors.

NeoGenomics, Inc. (NEO) traded down $0.04 during trading hours on Friday, reaching $8.86. 233,147 shares of the company’s stock traded hands, compared to its average volume of 311,421. The stock has a market cap of $715.65, a P/E ratio of -25.31, a PEG ratio of 12.36 and a beta of 0.85. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.99 and a current ratio of 2.14. NeoGenomics, Inc. has a 12 month low of $7.12 and a 12 month high of $11.63.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The business had revenue of $63.05 million for the quarter, compared to the consensus estimate of $63.11 million. During the same period in the prior year, the firm earned $0.04 EPS. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. research analysts anticipate that NeoGenomics, Inc. will post 0.04 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on NEO. BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 18th. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, October 13th. BTIG Research lowered shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $10.33.

ILLEGAL ACTIVITY NOTICE: This piece was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://weekherald.com/2017/12/30/neogenomics-inc-neo-holdings-increased-by-uniplan-investment-counsel-inc.html.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply